… as the third-line and post-third-line treatments after resistance … in the combination therapy
compared with monotherapy. In a … gefitinib or erlotinib were enrolled and then received gefitinib …

… gefitinib and erlotinib was not used in the first-line therapy, it had priority. The third-line therapy
… A Phase III, open-label, 3-center trial compared the efficacy and tolerability of osimertinib …

… treatment in EGFR-positive NSCLC and second- or third-line … dose erlotinib achieved higher
concentrations in CSF compared … gefitinib at the dose of 750 mg OD for safety and efficacy in …

… Osimertinib was the only TKI that showed efficacy against the … Therefore, it was approved as
a third-line treatment in 2003. … ) compared gefitinib with placebo and found no differences in …

… A comparison of the treatment efficacies in the current study … , we compared afatinib to pooled
data for gefitinib and erlotinib. … -line, and third-line therapies were also similar between the …

… tested for its efficacy as second- and third-line therapy. In the … ], it was compared to erlotinib
in patients with advanced NSCLC … in NSCLC was compared to that of erlotinib and gefitinib, …

… Osimertinib has demonstrated efficacy in patients with … osimertinib as a second- or third-line
therapy are included. The “… PFS and OS comparisons between the chemotherapy-osimertinib …

… There are no clinical study comparing the efficacy of erlotinib … line, 3.4 months in the third
line, and 3.5 months in the fourth … 11.1–46.0) with gefitinib. There was no statistically significant …

… survival (PFS) and objective response rates (ORRs) of patients with EGFR mutations have
been improved by EGFR-TKI therapy, including gefitinib, erlotinib, and afatinib, compared with …

… erlotinib had a higher clinical efficacy than gefitinib. Another study, ICOGEN, compared the
efficacy and safety of Icotinib and gefitinib in second - and third-line treatments of advanced …